• 1. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

Recent Advances in the Study of 2-Bromo-3H-imidazo[4,5-c]pyridine (CAS: 1557344-85-0) and Its Applications in Chemical Biology and Pharmaceutical Research

The compound 2-Bromo-3H-imidazo[4,5-c]pyridine (CAS: 1557344-85-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications as a key intermediate in the synthesis of bioactive molecules. This heterocyclic compound, characterized by its imidazopyridine core and bromine substituent, serves as a crucial building block for the development of novel therapeutic agents, particularly in the areas of oncology, infectious diseases, and central nervous system (CNS) disorders. Recent studies have highlighted its potential in the design of kinase inhibitors, antiviral agents, and modulators of protein-protein interactions.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-Bromo-3H-imidazo[4,5-c]pyridine in the synthesis of potent and selective inhibitors targeting Bruton's tyrosine kinase (BTK), a key player in B-cell signaling pathways. The researchers utilized the bromine moiety as a handle for further functionalization via palladium-catalyzed cross-coupling reactions, enabling the rapid generation of a diverse library of BTK inhibitors with improved pharmacokinetic properties. The study reported several derivatives with nanomolar potency and favorable in vivo efficacy in murine models of B-cell malignancies.

In the realm of antiviral drug discovery, a recent patent application (WO2023056789) disclosed the use of 2-Bromo-3H-imidazo[4,5-c]pyridine derivatives as broad-spectrum inhibitors of RNA-dependent RNA polymerase (RdRp), showing particularly promising activity against SARS-CoV-2 and other coronaviruses. The structural flexibility of this scaffold allowed for optimization of both antiviral potency and metabolic stability, addressing key challenges in the development of next-generation antiviral therapeutics.

From a synthetic chemistry perspective, novel methodologies for the functionalization of 2-Bromo-3H-imidazo[4,5-c]pyridine have been developed, as reported in a 2024 ACS Catalysis paper. The study introduced a photoredox-catalyzed C-H activation strategy that enables direct arylation at the C-5 position of the imidazopyridine ring, significantly expanding the chemical space accessible from this versatile intermediate. This methodological advance has important implications for medicinal chemistry campaigns aiming to explore structure-activity relationships in drug discovery programs.

Ongoing research efforts are also investigating the potential of 2-Bromo-3H-imidazo[4,5-c]pyridine-based compounds as modulators of epigenetic targets. Preliminary data presented at the 2024 American Chemical Society National Meeting revealed promising activity of certain derivatives against histone demethylases, suggesting potential applications in cancer therapy and neurological disorders. The unique electronic properties of the imidazopyridine core appear to contribute to selective binding at these challenging targets.

As the field progresses, several challenges remain to be addressed, including the optimization of physicochemical properties and the development of more sustainable synthetic routes for 2-Bromo-3H-imidazo[4,5-c]pyridine production. Recent advances in continuous flow chemistry and biocatalysis offer promising solutions to these challenges, potentially enabling broader access to this valuable building block for drug discovery efforts.

In conclusion, 2-Bromo-3H-imidazo[4,5-c]pyridine (CAS: 1557344-85-0) continues to emerge as a privileged scaffold in medicinal chemistry, with recent studies expanding its applications across multiple therapeutic areas. The compound's versatility in synthetic transformations and its ability to confer desirable pharmacological properties make it an increasingly important tool in the development of next-generation therapeutics. Future research directions likely will focus on further exploration of its structure-activity relationships and the development of novel synthetic methodologies to access more diverse derivatives.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)